Abstract: A biocompatible tissue repair stimulating implant or “scaffold” device is used to repair tissue injuries, particularly injuries to ligaments, tendons, and nerves. Such implants are especially useful in methods that involve surgical procedures to repair injuries to ligament, tendon, and nerve tissue in the hand and foot. The repair procedures may be conducted with implants that contain a biological component that assists in healing or tissue repair.

Abstract: The present invention is directed to medical devices and pharmaceutical compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry.

Abstract: This invention relates to novel compounds that are hydroxyethylamino sulfonamide derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel hydroxyethylamino sulfonamide derivatives that are derivatives of darunavir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a human immunodeficiency virus (HIV) protease inhibitor, such as darunavir.

Abstract: The present invention relates to solid pharmaceutical dosage forms which can be administered orally and comprise 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide in amorphous form and/or thermodynamically metastable crystal modification and have rapid release of active ingredient, and to process for the production thereof, the use thereof as medicament, the use thereof for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and to the use thereof for producing a medicament for the prophylaxis, secondary prophylaxis and/or treatment of disorders.

Abstract: This invention relates to fat containing consumable food products comprising ?-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without ?-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention.

Abstract: Abstract Provided is an oil-based cosmetic preparation which retains a smooth feel. Provided is an oil-based cosmetic preparation containing the following components (A), (B), and (C): (A) a cellulose derivative having a cellulose skeleton in a main chain, in which 67 mol % or more in total hydroxyl groups are substituted with a group —O-M-R, wherein M represents CH2 or a carbonyl group C?O, and R represents a straight or branched alkyl or alkenyl group having 3 to 40 carbon atoms; (B) an ester oil which is liquid at 25° C.; and (C) a hydrocarbon oil which is liquid at 25° C., in which a weight ratio (B)/(C) of the component (B) to the component (C) is 8/1 to 1/4.

Abstract: The present invention provides methods for enhancing chemical reactions of molecules, e.g., biomolecules, with destructible surfactants. The chemical reactions may involve and/or be associate with analysis, e.g., solubilizing, separating, purifying and/or characterizing the molecules. In one aspect, the anionic surfactants of the present invention may be selectively broken up at relatively low pH. The resulting breakdown products of the surfactants may be removed from the molecule/sample with relative ease. The invention has applicability in a variety of analytical techniques.

Abstract: Provided is a medicated patch containing a medicinal agent and an adhesive base material and having an acid value of no greater than 28, where the medicinal agent is varenicline or a pharmaceutically acceptable salt of varenicline.

Abstract: A material useful as a MRI contrast agent used for medical imaging, drug delivery platform or other functions are provided as a class of non-gadolinium and non-iron oxide based materials that comprise Prussian blue materials or analogue materials. The materials may be used as T1-weighted and/or T2-weighted MRI contrast agents for imaging, including cellular imaging, in clinical diagnosis and biomedical research applications. The agent is a compound created from Prussian blue materials that is non-toxic, and can be internalized by cells through endocytosis. The Prussian blue materials may also be used for drug delivery applications. The Prussian blue materials may be administered orally to a subject in either medical imaging or drug delivery applications or dual modality MRI-Fluorescence imaging agent.

Abstract: Present invention provides a composition for a cosmetic comprising a fluorine-containing silicone polymer having a three-dimensional, cross-linked structure, prepared by addition polymerizing the following (A), (B) and (C) and containing 10 to 30 mass % of the fluorine atoms, relative to a total mass of (A) to (C), (A) a vinyl group-containing organopolysiloxane represented by the following formula (1): (B) an organohydrogenpolysiloxane represented by the following formula (2): and (C) an organopolysiloxane having a reactive group on one end alone and represented by the following formula (3), and further comprising (D) a low viscosity silicone oil with a dynamic viscosity of 50 mm2/s or less at 25 degrees C.

Abstract: The present invention relates to a pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and/or integumentary structures of the skin and/or mucous membranes, including mucous membranes of the digestive tract, uro-genital tract and bronchial system and/or conjunctiva, containing a lipophilic phase in a quantity of 1-10% by weight, a mixture of surfactant and co-surfactant in a quantity of 1-50% by weight, a hydrophilic phase in a quantity of 40-80% by weight and, as active ingredient, cyclosporin and/or derivatives thereof in a concentration of 0.1-20% by weight.

Abstract: Hydrophobic ?(1?4)glucopyranose polymers useful for the preparation of implantable or injectable medical articles are described. The hydrophobic ?(1?4)glucopyranose polymer includes pendent groups having hydrocarbon groups and terminal amine or hydroxyl groups. Biodegradable matrices can be formed from these polymers, and the matrices can be used for the preparation of implantable and injectable medical devices wherein the matrix is capable of degrading in vivo. Matrices including and capable of releasing a bioactive agent in vivo are also described.

Abstract: Compositions are provided which stimulate bone growth. Also provided are methods for utilizing the compositions for filling in bone defects, promoting rapid fusion of bone fractures, grafts, and bone-prostheses, and promoting strengthening of osteoporotic bones.

Abstract: Poly(beta-amino esters) are end-modified to form materials useful in the medical as well as non-medical field. An amine-terminated poly(beta-amino ester) is reacted with an electrophile, or an acrylate-terminated poly(beta-amino ester) is reacted with a nucleophile. The inventive end-modified polymers may be used in any field where polymers have been found useful including the drug delivery arts. The end-modified polymers are particularly useful in delivery nucleic acids such as DNA or RNA. The invention also provides compositions including the inventive end-modified polymers, methods of preparing the inventive polymers, and method of using the inventive polymers.

Abstract: The present application teaches a coating having a biologically compatible compound conjugated to, or blended with, a polymer, wherein the polymer includes at least one olefin-derived unit and at least one unit derived from a vinyl alcohol, an allyl alcohol, or derivatives thereof.

Abstract: A synergistic antimicrobial composition comprising: (a) a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phoshponium salts and tris(hydroxymethyl)phosphine; and (b) tris(hydroxymethyl)nitromethane.

Abstract: Poly(?-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are described. Methods of preparing these polymers from commercially available starting materials are also provided. These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the poly(amine) nature of these polymers, they are particularly suited for the delivery of polynucleotides. Nanoparticles containing polymer/polynucleotide complexes have been prepared. The inventive polymers may also be used to encapsulate other agents to be delivered. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

Abstract: Here the inventors provide a composition for topical application to the skin of animal comprising stearidonic acid in combination with one or octadecatrienoic acids (CODTAs). Preferably the composition comprises echium oil as a source of the stearidonic acid, and a plant lipid as a source of octadecatrienoic acid, such as borage oil (Borago officinalis), wheat germ oil (Triticum vulgare) rosehip oil (refined; Rosa mosqueta), jacaranda oil (Jacandra mimosi folia), and/or calendula oil (Calendula officinalis). The composition of the invention increases collagen I secretion and thus has particular utility for promoting collagen production in skin.

Abstract: Cosmetic compositions comprising water-redispersible polymers are provided, as well as methods for using such compositions in cosmetics that afford powder-to-liquid and moisture-resistant benefits. These cosmetics can provide easier portability, as well as long wear benefits when topically applied to the skin or hair.

Abstract: Pharmaceutical compositions that have excellent storage stability even though they include a active component that is susceptible to degradation in an acidic environment are disclosed. The stabilized pharmaceutical composition of the invention includes a ring-opened 7-substituted-3,5-dihydroxyheptanoic or a ring-opened 7-substituted-3,5-dihydroxyheptenoic acid, or a pharmaceutically acceptable salt thereof, as an active component and a stabilizing effective amount of at least one amido-group containing polymeric compound or at least one amino-group containing polymeric compound, or combination thereof; wherein the stabilized pharmaceutical composition does not contain a stabilizing effective amount of another stabilizer or a combination of other stabilizers.